Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
03.02. | MHRA approves CSL's Andembry to treat angioedema attacks in HAE patients | ||
03.02. | FlyPharma 2025 Amsterdam officially announced as contracts are signed with host sponsors | ||
03.02. | Optimising business partnerships for success and sustainability | ||
31.01. | Amgen's Blincyto granted EC approval for new acute lymphoblastic leukaemia indication | ||
31.01. | NICE approves Vertex's Casgevy one-time gene therapy for sickle cell disease | ||
31.01. | ICR researchers uncover new method for predicting bowel cancer risk in IBD patients | ||
31.01. | Keto, CAR-T and creativity: insights from ASH 2024 | ||
30.01. | UK access pathway launched to get new medicines to patients in 'shortest time possible' | ||
30.01. | Sanofi's Sarclisa combination approved by MHRA for newly diagnosed multiple myeloma | ||
30.01. | Roche shares overall survival results for Itovebi in advanced breast cancer | ||
30.01. | The AI tipping point in pharma marketing: balancing technology and trust | ||
29.01. | Biogen's higher dose spinal muscular atrophy regimen accepted for review by EMA/FDA | ||
29.01. | Novo Nordisk's Ozempic granted FDA approval in chronic kidney disease | ||
29.01. | Bayer UK launches digital educational hub to improve menopause support | ||
29.01. | Back to work | ||
28.01. | AstraZeneca/Daiichi Sankyo's Enhertu granted FDA approval in breast cancer | ||
28.01. | Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy | ||
28.01. | BMS presents promising data for immunotherapy combination in phase 3 colorectal cancer trial | ||
28.01. | The silent treatment - researching gene silencing for Alzheimer's, Parkinson's and motor neurone disease | ||
27.01. | Biogen/Eisai's Alzheimer's drug approved by FDA for monthly maintenance dosing | ||
27.01. | Pfizer shares positive late-stage results for Braftovi regimen in colorectal cancer | ||
27.01. | Havas Health Network launches Havas Life London | ||
27.01. | Promiscuous strategists | ||
24.01. | AbbVie and Neomorph enter molecular glue degrader partnership worth $1.64bn | ||
24.01. | AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe |